@colleenyoung Hi. Thank you for the valuable links to guidelines and the discussion.
Post biopsy, DREs, monitoring of PSA and imaging (mpMRI) were used over the past year for active surveillance. Another PSMA Ga68 PET scan is scheduled after two months.
The "Very Low Risk" / "Low Metastasis Risk" result of the Oncotype DX GPS has contributed to continuation of Active Surveillance, my personal hope being that current trials on immunotherapy, such as the one currently in progress on Prostvac for localized P Ca, could yield a viable modality for enhancing probability of keeping the disease confined to the organ. The active surveillance guidelines do not yet specifically mention GPS in their recommendations for active surveillance, risk being low or intermediate based on PSA score, Gleason score and viewability of lesion in a scan.
The PSA hovering at 12 levels after the biopsy, therefore, remains a concern.